Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment.

A novel small-molecule inverse agonist, HEP-50768, effectively targets MRGPRX4 and suppresses cholestatic itch in preclinical models.

• Why it matters: Chronic itch from cholestatic conditions significantly impacts patient quality of life, yet current treatments are limited, highlighting the need for targeted therapies.
• What they did: Researchers used high-throughput screening and structure-activity optimization to develop HEP-50768, with cryo-electron microscopy revealing its unique binding and inhibitory mechanisms.
• The result: HEP-50768 demonstrated strong suppression of bile-acid-induced pruritic behaviors in humanized rats and showed favorable safety profiles, supporting its progression to clinical trials.